BRPI0408774A - vacinas de dna contra crescimento tumoral e seus usos - Google Patents

vacinas de dna contra crescimento tumoral e seus usos

Info

Publication number
BRPI0408774A
BRPI0408774A BRPI0408774-7A BRPI0408774A BRPI0408774A BR PI0408774 A BRPI0408774 A BR PI0408774A BR PI0408774 A BRPI0408774 A BR PI0408774A BR PI0408774 A BRPI0408774 A BR PI0408774A
Authority
BR
Brazil
Prior art keywords
human
tumor growth
protein
cancer
dna
Prior art date
Application number
BRPI0408774-7A
Other languages
English (en)
Inventor
Rong Xiang
He Zhou
Ralph A Reisfeld
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BRPI0408774A publication Critical patent/BRPI0408774A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

"VACINAS DE DNA CONTRA CRESCIMENTO TUMORAL E SEUS USOS". Uma vacina de DNA adequada para despertar uma resposta imune contra células cancerosas compreende uma construção de DNA que codifica operacionalmente uma proteína da família de inibidor de apoptose associado a câncer e um produto de gene imunoativo, como uma citocina ou um ligante para um receptor natural de superfície de célula assassina, em um veículo farmaceuticamente aceitável. Uma citocina preferida é CCL21. Ligantes preferidos para um receptor natural de superfície de célula assassina incluem MICA humana, MICB humana, ULBP1 humana, ULBP2 humana, e ULBP3 humana. A proteína da família de inibidor de apoptose associado a câncer (IAP) é preferivelmente uma proteína sobrevivente ou proteína viva. Também é descrito um método de inibição de crescimento tumoral pela administração da vacina da invenção a um mamífero.
BRPI0408774-7A 2003-03-24 2004-03-24 vacinas de dna contra crescimento tumoral e seus usos BRPI0408774A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45700903P 2003-03-24 2003-03-24
PCT/US2004/008932 WO2004099389A2 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0408774A true BRPI0408774A (pt) 2006-03-28

Family

ID=33434911

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408774-7A BRPI0408774A (pt) 2003-03-24 2004-03-24 vacinas de dna contra crescimento tumoral e seus usos

Country Status (18)

Country Link
US (2) US8716254B2 (pt)
EP (1) EP1622648B1 (pt)
JP (1) JP4616827B2 (pt)
KR (1) KR101199789B1 (pt)
CN (1) CN1791433B (pt)
AT (1) ATE472339T1 (pt)
AU (1) AU2004236636B2 (pt)
BR (1) BRPI0408774A (pt)
CA (1) CA2519953C (pt)
DE (1) DE602004027902D1 (pt)
DK (1) DK1622648T3 (pt)
ES (1) ES2345200T3 (pt)
MX (1) MXPA05010255A (pt)
PL (1) PL1622648T3 (pt)
PT (1) PT1622648E (pt)
RU (1) RU2343195C2 (pt)
WO (1) WO2004099389A2 (pt)
ZA (1) ZA200508579B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294805B2 (en) 2004-05-28 2012-02-16 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR100790377B1 (ko) * 2006-02-15 2008-01-02 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주를 함유하는항바이러스용 조성물
CA2657217A1 (en) * 2006-06-21 2007-12-27 The Scripps Research Institute Dna composition against tumor stromal antigen fap and methods of use thereof
WO2008003473A2 (en) * 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
EP2102234A2 (en) * 2006-11-28 2009-09-23 GHC Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2009232774B2 (en) 2008-03-31 2014-05-29 Tella Inc. Partial peptide of Survivin presented on MHC class II molecule and use thereof
CA2757224C (en) * 2009-03-27 2016-12-06 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof
RU2431669C2 (ru) * 2009-06-23 2011-10-20 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный университет им. В.И. Ульянова-Ленина" Способ получения лекарственного препарата генетически модифицированных клеток
AU2010284428B2 (en) * 2009-08-17 2014-09-11 The Penn State Research Foundation Use of NKG2D inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
KR20130087517A (ko) * 2010-06-25 2013-08-06 백시바디 에이에스 동종이합체 단백질 구조물
CN102210862B (zh) * 2011-06-01 2013-06-12 中国人民解放军南京军区福州总医院 基于Livin的免疫刺激复合物及其制备方法和应用
BR112015020516A2 (pt) * 2013-02-26 2017-10-10 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
WO2014144885A2 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
WO2014163213A1 (en) * 2013-04-05 2014-10-09 Kyushu University, National University Corporation Anti-tumor dna vaccine
EP3016973A1 (en) * 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
CN113491766A (zh) * 2014-03-14 2021-10-12 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
CN106661544B (zh) * 2014-08-29 2020-03-27 加利福尼亚大学董事会 用于牲畜生产系统的疫苗
EP3291842A4 (en) 2015-05-07 2019-01-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. SURVIVIN VACCINE VARIANT FOR THE TREATMENT OF CANCER
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
UA125062C2 (uk) 2015-10-01 2022-01-05 Потенза Терапеутікс, Інк. Анти-tigit антигензв'язуючі білки і способи їх застосування
JP7092281B2 (ja) * 2017-02-07 2022-06-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN110448689A (zh) * 2019-08-06 2019-11-15 太仓美诺恒康生物技术有限公司 mRNA疫苗及其试剂盒、应用
WO2021052496A1 (zh) * 2019-09-20 2021-03-25 科济生物医药（上海）有限公司 细胞因子调控表达的免疫效应细胞
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
RU2770490C1 (ru) * 2021-07-14 2022-04-18 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" Рекомбинантная плазмидная ДНК pET19b-Surv-OL, обеспечивающая синтез гибридного белка сурвивин-обелин (Surv-OL) и гибридный белок, связываемый анти-сурвивин антителами и обладающий биолюминесцентной активностью
CN116077534B (zh) * 2023-01-31 2024-08-27 大连工业大学 一种凝结芽孢杆菌的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) * 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
GB9104596D0 (en) * 1991-03-05 1991-04-17 Wellcome Found Production of recombinant proteins
US5702917A (en) * 1992-01-27 1997-12-30 Icos Corporation Polynucleotides encoding human ICAM-4
RU2077340C1 (ru) * 1993-08-06 1997-04-20 Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Способ получения специфической сыворотки для лечения, диагностики и профилактики вирусной геморрагической болезни кроликов и набор для диагностики болезни
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
RU2219942C2 (ru) * 1996-02-24 2003-12-27 Берингер Ингельхайм Интернациональ Гмбх Лекарственный состав с иммуномодуляторным действием, содержащий пептиды и вспомогательные средства
CA2271783C (en) * 1996-11-20 2013-04-16 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
ATE421888T1 (de) * 1997-08-13 2009-02-15 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
DE69831754T2 (de) * 1997-12-17 2006-06-29 Immunex Corp., Thousand Oaks Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
WO2000003693A1 (en) * 1998-07-14 2000-01-27 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
IT1303683B1 (it) * 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
CA2356688A1 (en) * 1998-12-18 2000-06-29 Haarmann + Reimer G.M.B.H. Encapsulated flavour and/or fragrance preparations
AU2001273102A1 (en) * 2000-06-29 2002-01-14 The Salk Institute For Biological Studies Crystal structure of survivin
EP1256354A1 (en) * 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
WO2003031569A2 (en) * 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
EP2301573A1 (en) * 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
EP1572736A2 (en) * 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation

Also Published As

Publication number Publication date
RU2343195C2 (ru) 2009-01-10
EP1622648B1 (en) 2010-06-30
DE602004027902D1 (de) 2010-08-12
JP2006523217A (ja) 2006-10-12
ES2345200T3 (es) 2010-09-17
WO2004099389A3 (en) 2005-09-29
ATE472339T1 (de) 2010-07-15
CA2519953A1 (en) 2004-11-18
DK1622648T3 (da) 2010-09-06
US9655815B2 (en) 2017-05-23
US8716254B2 (en) 2014-05-06
US20140322249A1 (en) 2014-10-30
CN1791433A (zh) 2006-06-21
PL1622648T3 (pl) 2010-11-30
WO2004099389A2 (en) 2004-11-18
AU2004236636A1 (en) 2004-11-18
AU2004236636B2 (en) 2010-02-04
KR20050121694A (ko) 2005-12-27
EP1622648A2 (en) 2006-02-08
EP1622648A4 (en) 2007-02-14
JP4616827B2 (ja) 2011-01-19
CA2519953C (en) 2016-01-05
PT1622648E (pt) 2010-08-31
ZA200508579B (en) 2007-04-25
MXPA05010255A (es) 2005-12-14
KR101199789B1 (ko) 2012-11-09
US20040192631A1 (en) 2004-09-30
CN1791433B (zh) 2010-05-26
RU2005132578A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
MXPA05010255A (es) Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas.
Finn et al. Prophylactic cancer vaccines
KR102049928B1 (ko) 효모-muc1 면역요법 조성물 및 그 용도
Lollini et al. Vaccines for tumour prevention
Grauer et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate‐pulsed dendritic cells in a murine glioma model
ES2328025T3 (es) Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
Bolesta et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery
ES2460899T3 (es) Inmunoterapia basada en células cancerosas alógenas
CY1114912T1 (el) Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου
CN109073637A (zh) 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法
Morris et al. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer
Loukinov et al. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant
Venuti et al. Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
Ding et al. Coadministration of the fungal immunomodulatory protein FIP‐Fve and a tumour‐associated antigen enhanced antitumour immunity
JP2018508533A (ja) 方法
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
Lopes et al. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site
Kim et al. A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells
Nelson et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the ‘self’tumor-associated antigen, neu in a rat mammary tumor model
Pati et al. mRNA vaccines in cancer immunotherapy: recent advances, clinical translation, and future perspectives
EP2804626B1 (en) Autologous cancer cell vaccine
Yang et al. Effect of chronic endogenous antigen stimulation on CAR T cell persistence and memory formation
Bolhassani et al. Small heat shock proteins B1 and B6: Which one is the most effective adjuvant in therapeutic HPV vaccine?
BR112022006177A2 (pt) Kir3dl3 é um receptor inibidor do sistema imune e do mesmo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL